Cassava Sciences Inc vs Fox Corp Class A — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Fox Corp Class A trades at $56.67 (market cap $22.28B). The key difference: Fox Corp Class A is far larger — about 419.3× Cassava Sciences Inc's market cap, and Fox Corp Class A pays a 1% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | FOXA | |
|---|---|---|
Market Cap | $53.14M | $22.28B |
Sector | Health | Media |
52-Week High | $4.64 | $76.11 |
52-Week Low | $1.09 | $48.79 |
Enterprise Value | -$33.43M | $26.25B |
Dividend Yield | — | 1% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Fox Corporation (FOXA) trades at $56.69, up 3.32% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results, beating EPS estimates, and completed a transformative $22 billion acquisition of Roku in June 2026. Fundamentals show revenue growth to $16.3B in 2025 with a 13.88% net margin, while valuation metrics appear reasonable with a P/E of 14.73 and EV/EBITDA of 8.42.
The outlook balances strategic positioning through the Roku acquisition against integration risks and leverage concerns. Analyst consensus is evenly split between Buy and Hold with a $67.80 price target suggesting 19.6% upside, but technical indicators remain bearish and projected 2026 cash flow turns negative. Key risks include streaming competition, advertising cyclicality, and debt servicing from the Roku deal.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →